Flow cytometry has dramatically improved scientists’ ability to characterize individual cells from complex tissues. Its versatility and ease-of-use has led scientists to connect flow cytometry with technologies such as CRISPR screens and single-cell transcriptomics to answer intricate biological questions and improve existing treatments, such as stem cell therapies, for a variety of diseases. In this webinar, brought to you by BD Biosciences, Audrey Parent and Rasul Chaudhry will highlight how they leverage flow cytometry to improve stem cell therapies for diabetes and multiple sclerosis.
Topics to be covered
• Immunoengineering stem cell-derived β cells for cell therapy and disease modeling
• Developing neural stem cell therapies for multiple sclerosis
Audrey Parent, PhD
Assistant Professor, Diabetes Center, University of California, San Francisco
Audrey Parent is an assistant professor at the UCSF Diabetes Center. She received her PhD in biochemistry from the University of Sherbrooke in Québec, Canada and carried out her postdoctoral research at the UCSF Diabetes Center in the laboratories of Matthias Hebrok and Mark Anderson. Parent studies the mechanisms that lead to the initiation and progression of human type 1 diabetes and develops methods to generate stem cell-derived pancreatic beta cells for cell replacement therapies. She uses genetic engineering tools like CRISPR/Cas9 to better understand how specific genes affect the immune response to beta cells in human autoimmune diseases like type 1 diabetes.
G. Rasul Chaudhry, PhD
Professor, Department of Biological Sciences, Co-director, Institute for Stem Cells and Regenerative Medicine, Oakland University
G. Rasul Chaudhry is a professor of molecular biology in the Department of Biological Sciences, and co-director of the Institute for Stem Cell and Regenerative Medicine at Oakland University. Chaudhry studies stem cell biology and develops stem cell-based therapies for degenerative diseases, such as autoimmune hepatitis, multiple sclerosis, Parkinson’s disease, and retinal degenerative diseases.